Pharmacokinetic and safety evaluation of SangCya vs Neoral or Sandimmune in stable renal transplant recipients

By Gaston R.   Alloway R.R.   Gaber A.O.   Rossi S.J.   Schroeder T.J.   Irish W.D.   Canafax D.M.   First M.R.  

Transplantation Proceedings, Vol. 31, Iss. 1, 1999-02 ,pp. : 326-327

Elsevier

Access to resources Recommend Favorite

Conversion of stable renal transplant recipients from sandimmune to sang-35, a neoral-equivalent cyclosporine formulation, using a dose-adjusted method

By First M.R.   Weiskittel P.   Shah M.   Peddi V.R.   Canafax D.   Schroeder T.J.  

Transplantation Proceedings, Vol. 30, Iss. 8, 1998-12 ,pp. : 3955-3957

Elsevier

Access to resources Recommend Favorite

Nine-month follow-up of SangCya (Sang-35) in kidney transplant patients after conversion from sandimmune

By First M.R.   Weiskittel P.   Burton M.L.   Shah M.B.   Dreyer D.   Fleck P.   Bey C.   Peddi V.R.   Canafax D.M.   Schroeder T.J.  

Transplantation Proceedings, Vol. 31, Iss. 1, 1999-02 ,pp. : 324-325

Elsevier

Access to resources Recommend Favorite

Conversion of stable renal transplant recipients from sandimmune to sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method

By First M.R.   Weiskittel P.   Burton M.   Shah M.   Dreyer D.   Fleck P.   Bey C.   Peddi R.   Canafax D.   Schroeder T.J.  

Transplantation Proceedings, Vol. 30, Iss. 5, 1998-08 ,pp. : 1701-1705

Elsevier

Access to resources Recommend Favorite

Results of conversion from sandimmune to neoral in stable pediatric liver transplant recipients after two years

By Dunn S.P.   Falkenstein K.   Pierson A.   Cooney G.F.  

Transplantation Proceedings, Vol. 30, Iss. 5, 1998-08 ,pp. : 1962-1963

Elsevier

Access to resources Recommend Favorite